Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-969-3335
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.30 billion
Profitability
Miscellaneous
Employees21,230
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions
What is GRIFOLS S A/S's stock symbol?
GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."
How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?
GRIFOLS S A/S announced a Semi-Annual dividend on Wednesday, May 29th. Investors of record on Monday, June 10th will be given a dividend of $0.14 per share on Tuesday, June 18th. The ex-dividend date of this dividend is Friday, June 7th. View GRIFOLS S A/S's Dividend History.
When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?
GRIFOLS S A/S shares split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.
When is GRIFOLS S A/S's next earnings date?
What price target have analysts set for GRFS?
5 brokerages have issued 1-year price targets for GRIFOLS S A/S's stock. Their forecasts range from $19.00 to $22.50. On average, they anticipate GRIFOLS S A/S's share price to reach $20.75 in the next twelve months. This suggests that the stock has a possible downside of 5.6%. View Analyst Price Targets for GRIFOLS S A/S.
What is the consensus analysts' recommendation for GRIFOLS S A/S?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S.
Has GRIFOLS S A/S been receiving favorable news coverage?
News coverage about GRFS stock has trended negative this week, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for GRIFOLS S A/S.
Who are some of GRIFOLS S A/S's key competitors?
Some companies that are related to GRIFOLS S A/S include Zoetis (ZTS), Shire (SHPG), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Commonwealth Bank of Australia (CSLLY), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN) and Genmab A/S (GNMSF).
What other stocks do shareholders of GRIFOLS S A/S own?
Who are GRIFOLS S A/S's key executives?
GRIFOLS S A/S's management team includes the folowing people:
- Mr. Raimon Grifols Roura, Co-CEO & Exec. Director (Age 55)
- Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
- Mr. Víctor Grífols Deu, Co-CEO & Exec. Director (Age 42)
- Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
- Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs
Who are GRIFOLS S A/S's major shareholders?
GRIFOLS S A/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include AKO Capital LLP (1.83%), Pictet Asset Management Ltd. (1.00%), First Trust Advisors LP (0.74%), Farallon Capital Management LLC (0.45%), Bank of New York Mellon Corp (0.37%) and Price T Rowe Associates Inc. MD (0.30%).
Which major investors are selling GRIFOLS S A/S stock?
GRFS stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp, Bank of America Corp DE, Pictet Asset Management Ltd., CIBC Asset Management Inc, Van ECK Associates Corp, Renaissance Technologies LLC and BlackRock Inc..
Which major investors are buying GRIFOLS S A/S stock?
GRFS stock was acquired by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, Morgan Stanley, AKO Capital LLP, Marshall Wace LLP, UBS Group AG, Marshall Wace North America L.P., Citadel Advisors LLC and Farallon Capital Management LLC.
How do I buy shares of GRIFOLS S A/S?
Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GRIFOLS S A/S's stock price today?
One share of GRFS stock can currently be purchased for approximately $21.99.
How big of a company is GRIFOLS S A/S?
GRIFOLS S A/S has a market capitalization of $15.12 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S.
What is GRIFOLS S A/S's official website?
How can I contact GRIFOLS S A/S?
GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected]
MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)
MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
